Figure 3.

Rosuvastatin-treated subjects receiving a protease inhibitor (PI)–based antiretroviral therapy regimen had a statistically significant decrease in the proportion of CD14^DimCD16⁺ cells. Monocyte subsets were identified in fresh whole-blood samples using size and granularity, and by expression of CD14 and CD16. Proportions of patrolling (CD14^DimCD16⁺) monocytes were reduced in patients receiving PI-based antiretroviral therapy (ART) (−22%), but not in patients receiving non-PI-based ART (20%, P = .0252).